Cargando…

Clinician's guide to targeted estrogen receptor degradation using PROTAC in patients with estrogen receptor-positive metastatic breast cancer

PURPOSE OF REVIEW: Metastatic breast cancer (MBC) remains a major clinical challenge, necessitating the development of innovative therapeutic strategies. Estrogen receptor (ER) degradation using proteolysis-targeting chimeras (PROTAC) has emerged as a promising approach for overcoming acquired resis...

Descripción completa

Detalles Bibliográficos
Autor principal:	Grinshpun, Albert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	BREAST CANCER: Edited by Giuseppe Curigliano
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566586/ https://www.ncbi.nlm.nih.gov/pubmed/37427531 http://dx.doi.org/10.1097/CCO.0000000000000972

Ejemplares similares

Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor‐Positive Metastatic Breast Cancer
por: Jin, Liang, et al.
Publicado: (2020)

Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer
por: Xia, Song, et al.
Publicado: (2022)

Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor‐Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care‐BC): A Randomized Controlled Phase III Trial
por: Niikura, Naoki, et al.
Publicado: (2019)

Estrogen receptor and progesterone receptor status of breast cancer patients of eastern India: A multi-institutional study
por: Chatterjee, Koushik, et al.
Publicado: (2018)

Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers
por: Raj, Ganesh V, et al.
Publicado: (2017)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
por: Negi, Arvind, et al.
Publicado: (2022)

Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case‐Control Study in Northern and Eastern China and Implications for Chemoprevention
por: Wang, Fei, et al.
Publicado: (2017)

Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer
por: West, Malinda T, et al.
Publicado: (2023)

Differential impact of the expression of the androgen receptor by age in estrogen receptor–positive breast cancer
por: Tokunaga, Eriko, et al.
Publicado: (2013)

A Phase II Trial of Cabozantinib in Hormone Receptor‐Positive Breast Cancer with Bone Metastases
por: Xu, Jing, et al.
Publicado: (2020)

Prognostic Factors for Overall Survival in Patients with Hormone Receptor‐Positive Advanced Breast Cancer: Analyses From PALOMA‐3
por: Rugo, Hope S., et al.
Publicado: (2021)

Revisiting Androgen Receptor Signaling in Breast Cancer
por: Dai, Charles, et al.
Publicado: (2023)

Estrogen receptor, Progesterone receptor, and human epidermal growth factor receptor-2 status in breast cancer: A retrospective study of 5436 women from a regional cancer center in South India
por: Kumar, Rekha Vijay, et al.
Publicado: (2018)

Targeting mutant estrogen receptors
por: Wardell, Suzanne E, et al.
Publicado: (2019)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Validation of Residual Proliferative Cancer Burden as a Predictor of Long‐Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer
por: Miglietta, Federica, et al.
Publicado: (2020)

Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
por: Rugo, Hope S., et al.
Publicado: (2020)

Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
por: Shastry, Mythili, et al.
Publicado: (2022)

Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
por: Rassy, Elie, et al.
Publicado: (2022)

Cytoplasmic G Protein-Coupled Estrogen Receptor 1 as a Prognostic Indicator of Breast Cancer: A Meta-Analysis
por: Zhang, Duo, et al.
Publicado: (2022)

Genetic and environmental factors and serum hormones, and risk of estrogen receptor-positive breast cancer in pre- and postmenopausal Japanese women
por: Guo, Jiazhi, et al.
Publicado: (2017)

Long‐Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow‐Up
por: Finn, Richard S., et al.
Publicado: (2021)

Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine
por: Levin, Maren K, et al.
Publicado: (2015)

Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy
por: Kaufman, Peter A., et al.
Publicado: (2019)

Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer
por: Soliman, Hatem, et al.
Publicado: (2020)

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
por: Tripathy, Debu, et al.
Publicado: (2019)

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
por: Le Du, Fanny, et al.
Publicado: (2023)

Prognostic Factors in Patients with Metastatic Breast Cancer with Bone‐Only Metastases
por: Parkes, Amanda, et al.
Publicado: (2018)

Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment
por: Ji, Chenchen, et al.
Publicado: (2023)

Hormone Receptor Subtype in Ductal Carcinoma in Situ: Prognostic and Predictive Roles of the Progesterone Receptor
por: Hwang, Ki‐Tae, et al.
Publicado: (2021)

Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer
por: Ge, Xuan, et al.
Publicado: (2023)

Estrogen Receptor Mutations and Changes in Estrogen Receptor and Progesterone Receptor Protein Expression in Metastatic or Recurrent Breast Cancer
por: Umekita, Yoshihisa, et al.
Publicado: (1998)

Comparative Effectiveness of Palliative Chemotherapy in Metastatic Breast Cancer: A Real‐World Evidence Analysis
por: Feinberg, Bruce, et al.
Publicado: (2020)

Soluble interleukin-6 receptor mediated fatigue highlights immunological heterogeneity of patients with early breast cancer who undergo radiation therapy
por: Courtier, Nicholas, et al.
Publicado: (2018)

Clinical Outcomes of Metastatic Breast Cancer in Patients Having Imaging Liver Pseudocirrhosis with or without Evident Varices
por: Ma, Wei-Li, et al.
Publicado: (2022)

Real-World Effectiveness of Palbociclib Plus Aromatase Inhibitors in African American Patients With Metastatic Breast Cancer
por: Rugo, Hope S, et al.
Publicado: (2023)

Heat shock factor 1 (HSF1) cooperates with estrogen receptor α (ERα) in the regulation of estrogen action in breast cancer cells
por: Vydra, Natalia, et al.
Publicado: (2021)

The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer
por: Allred, D Craig, et al.
Publicado: (2004)

Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer
por: Datta, Jharna, et al.
Publicado: (2022)

Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination
por: Chowdhary, Mudit, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a09ktbd4fi63ncjqhok4ag65vd